Drug Trial Radar · NCT06031259
Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment
Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Mar 5, 2024
Primary completion
Jan 1, 2029
Study completion Jan 1, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 3 years, up to 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is an extension of two previous studies (HGT-HIT-046 \[NCT01506141\] and SHP609-302 \[NCT02412787\]). Participants must have completed one of the previous studies. The main aim of this study is to collect more information about the safety of the treatments, idursulfase-IT and elaprase, in children and adults with Hunter syndrome and cognitive impairment. Participants will receive the same treatment as in the previous studies.
Conditions
- Hunter Syndrome
Interventions
Idursulfase-ITDrug
Idursulfase-IT intrathecally via IDDD.
ElapraseDrug
Elaprase IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs) by Type and SeverityTime frame: Up to approximately 4.8 years
- Number of Participants with AEs Related to Idursulfase-ITTime frame: Up to approximately 4.8 years
- Number of Participants with AEs Related to the IDDDTime frame: Up to approximately 4.8 years
- Number of Participants with AEs Related to Device Surgical ProcedureTime frame: Up to approximately 4.8 years
- Number of Participants with AEs Related to IT Administration ProcessTime frame: Up to approximately 4.8 years
- Number of Participants with AEs Related to IV Elaprase InfusionTime frame: Up to approximately 4.8 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
M.A.G.I.C. Clinic
Calgary, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada
Hospital for Sick Children
Toronto, Ontario, Canada
Hopital Femme Mere Enfant
Bron, Auvergne-Rhône-Alpes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.